Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

SEAPI Incontinence Classification System

1-Year Postoperative Results Following Midurethral Sling Placement

Glass, Allison MD*; Durbin-Johnson, Blythe PhD; Rothschild, Jennifer MD, MPH*; Gomelsky, Alexander MD

Female Pelvic Medicine & Reconstructive Surgery: November 9, 2018 - Volume Publish Ahead of Print - Issue - p
doi: 10.1097/SPV.0000000000000656
Original Article: PDF Only
Buy
PAP

Objective There are limited long-term data that has examined postoperative quality-of-life measures following placement of midurethral sling (MUS) for stress urinary incontinence (SUI). The SEAPI incontinence questionnaire includes 5 data points that rate severity of specific urinary symptoms. Our aim was to describe changes in SEAPI questionnaire outcomes 1 year following sling placement.

Methods We retrospectively reviewed women who underwent MUS for SUI from 2005 to 2012. We included those women who had completed preoperative and postoperative (>12 months) SEAPI scores. Individual S, E, A, P, I score cure was defined as postoperative score of 0 (>0 preoperative). Logistic regression analysis was used to model the effects of patient characteristics on incontinence cure and S, E, A, P, I scores.

Results A total of 584 women were included. Median follow-up was 25.4 months (12–126.8 months). Follow-up duration and baseline S, P, and I scores were associated with significantly lower odds of overall incontinence cure, whereas rectocele grade has positive association (odds ratio, 1.31; P = 0.040). Type of sling did not impact overall incontinence cure or cure of individual SEAPI scores.

Conclusions Preoperative S, P, and I scores had negative association with stress incontinence cure. Cure of individual S, E, A, P, I scores was impacted differently by various patient factors. The SEAPI questionnaire provides a unique profile of patient-reported and functional measures in women with SUI and may be helpful in those who undergo MUS.

From the Departments of *Urology and

Public Health Sciences, University of California–Davis, Sacramento, CA; and

Department of Urology, Louisiana State University Health–Shreveport, Shreveport, LA.

Correspondence: Allison Glass, MD, Department of Urology, 4860 Y Street, Suite 3500, Sacramento, CA 95817. E-mail: asglass@ucdavis.edu.

The authors have declared they have no conflicts of interest.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.